CV Date	26/10/2023

Part A. PERSONAL INFORMATION

First Name	JULIA MARÍA		
Family Name	ALMEIDA PARRA		
Sex	Female	Date of Birth	14/06/1964
ID number Social Security, Passport			
URL Web	https://www.cicancer.org/grupo?id=79		
Email Address	jalmeida@usal.es		
Open Researcher and Contributor ID (ORCID)	0000-0003-3124-8917		

A.1. Current position

Job Title	Catedrática de Universidad / Full Professor		
Starting date	2019		
Institution	Universidad de Salamanca / University of Salamanca		
Department / Centre	Medicine / Faculty of Medicine and Cancer Reserach Center		
Country		Phone Number	
Keywords	Natural sciences and health sciences		

A.3. Education

Degree/Master/PhD	University / Country	Year
Licenciatura en Medicina y Cirugía / Bach Medicine and Surgery	University of Salamanca	1988

Part B. CV SUMMARY

Julia Almeida graduated in Medicine and Surgery in 1988 at the University of Salamanca (USAL) with the highest honor, obtained her PhD Degree (USAL) in 1994, and in the same year she obtained her medical specialization in Hematology and Hemotherapy. She is currently Full Professor at the Department of Medicine of the University of Salamanca and is part (since around 25 years) of a research group (recognized as a Consolidated Research Unit by the Consejeria de Educación of Junta de Castilla y León), ascribed to the Cancer Research Center (IBMCC, USAL-CSIC) and integrated in the Instituto de Investigación Biomédica de Salamanca (IBSAL-ISCIII); she is recognized as one of the “emergent” groups at IBMCC, and is the current President of the Iberian Society for Cytometry (SIC).

Her research activity is focused since more than 20 years on “Immunology and Cancer”; in particular, J. Almeida is the responsible in her team within the whole group (named, “CITÓMICA” that is composed of more than 30 researchers, ultimately coordinated by Orfao) for the research lines focused on mature T/NK- and B-cell-derived tumors (**chronic lymphoproliferative disorders , from the onto-pathogenesis to clinical settings**), aiming at: i) the identification of mechanisms involved in the transformation/evolution of reactive to clonal and malignant conditions (i.e. the early stages of cancer, both prior to the onset of the disease and before recurrence after therapy), ii) phenotypic, genetic/molecular and functional characterization of these cells and iii) its translation to diagnosis, classification and treatment monitoring of these neoplasms; iv) the biological characterization of their normal (T/NK- and B-) cell counterparts; and v) the role of the immune system in the control and progression of the disease, with special focus on hematological malignancies. More specifically, the main lines of research of Julia Almeida include: i) the identification of altered protein expression profiles in leukemia cells that might be used for the diagnosis and classification (as well as MRD detection), ii) detailed dissection of the distinct compartments of immune cells in blood and other human lymphoid tissues, and their functional characterization, leading to iii) the development of new tools for the diagnosis and monitoring of hematological malignancies. Because of her scientific activity, Julia Almeida has published near 30 international scientific papers in the last 5 years, from which more than 65% are Q1, with a mean impact factor of around 7, and registered

3 patents (2 of them licensed), with a total of near 160 articles published in international indexed scientific journals (PI H-index of 47 with >7,000 citations).

J.Almeida is a member of: **i)** the **EuroFlow Consortium** (an European collaborative group) since its creation in 2006, which aims at **standardization and automation in flow cytometry**, to improve current flow cytometry strategies applied to the diagnosis, classification and monitoring after treatment of patients with malignant hemopathies (leukemias and lymphomas); specifically, she is the responsible person at EuroFlow for the design and development of the T- and NK-cell CLPD panels. Recently she has promoted active and stable collaborations with international groups interested in B- and T/NK-cell mature leukemias and lymphomas, such as the EORTC-CTL-task Force for the study of cutaneous T-cell lymphomas; and **ii) ECRIN-M3**, which brings together researchers from Salamanca (Spain), Milan (Italy), Southampton and Leeds (United Kingdom) focused on the study of monoclonal B-cell lymphocytosis and its relationship with chronic lymphocytic leukemia and other lymphoproliferative syndromes, and in which Julia Almeida is Co-IP of the Spanish group.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (nº x / nº y): position / total authors. If applicable, indicate the number of citations

1 **Scientific paper**. OLIVA-ARIZA G; FUENTES-HERRERO B; LECREVISSE Q; et al; (32/32) ALMEIDA J * (AC). 2023. Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis. Am J Hematol.Epub ahead of print. https://doi.org/10.1002/ajh.27119

2 **Scientific paper**. Damasceno D; Teodosio C; van den Bossche WBL; et al; *Last authors; (15/16) Orfao A*. 2019. Distribution of subsets of blood monocytic cells throughout cells.Journal of Allergy and Clinical Immunology (JACI). 144-1, pp.320-323. https://doi.org/10.1016/j.jaci.2019.02.030

3 **Scientific paper**. Ignacio Criado; Arancha Rodriguez Caballero; Laura Gutierrez; et al; * Igual Contribución; (13/14) Alberto Orfao *. 2018. Low-count monoclonal B-cell lymphocytosis persists after 7 years of follow-up and is associated with a poorer outcome.HAEMATOLOGICA. 103-7, pp.1198-1208. https://doi.org/10.3324/haematol.2017.183954

4 **Scientific paper**. Ignacio Criado; Elena Blanco; Arancha Rodriguez Caballero; et al; * Igual Contribución; (14/16) Julia Almeida *. 2018. Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. LEUKEMIA. 32-12, pp.2701-2705. https://doi.org/10.1038/s41375-018-0164-3

5 **Scientific paper**. M; C; D; et al; (19/19) M (AC). 2023. Predominantly Pro-Inflammatory Phenotype with Mixed M1/M2 Polarization of Peripheral Blood Classical Monocytes and Monocyte-Derived Macrophages among Patients with Excessive Ethanol Intake. Antioxidants. 12, pp.1708. https://doi.org/10.3390/antiox12091708

6 **Scientific paper**. 2023. Tgd LGL leukemia identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. Blood. 141-9, pp.1036-1046. https://doi.org/10.1182/blood.2021013489

7 **Scientific paper**. 2023. High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients. Blood. 141-3, pp.309-314. https://doi.org/10.1182/blood.2022017439

8 **Scientific paper**. 2022. Age- and Sex-Matched Normal Leukocyte Subset Ranges in the General Population Defined with the EuroFlow Lymphocyte Screening Tube (LST) for Monoclonal B-Cell Lymphocytosis (MBL) vs. Non-MBL Subjects. Cancers (Basel). MDPI. 15, pp.58. https://doi.org/10.3390/cancers15010058

9 **Scientific paper**. 2022. Novel genes and sex differences in COVID-19 severity. Hum Mol Genet. https://doi.org/10.1093/hmg/ddac132

10 **Scientific paper**. 2022. Development of a standardized and validated flow cytometry approach for monitoring of innate myeloid immune cells in human blood. Frontiers in Immunology. 13-935879, pp.1-23. https://doi.org/10.3389/fimmu.2022.935879
11 **Scientific paper**. 2022. High-sensitive TRBC1-based flow cytometric assessment of T-cell clonality in Tαβ-large granular lymphocytic leukemia. Cancers (Basel). 13, pp.3479. https://doi.org/10.3390/cancers14020408
12 **Scientific paper**. 2022. Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers. Revista espanola de cardiologia (English ed.). 75-9, pp.734-746. https://doi.org/10.1016/j.rec.2021.11.001
13 **Scientific paper**. 2021. Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome. Blood. 138-24, pp.2539-2554. https://doi.org/10.1182/blood.2021012286
14 **Scientific paper**. 2021. The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. Front Oncol.26-11, pp.723722. https://doi.org/10.3389/fonc.2021.723722
15 **Scientific paper**. 2021. Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation. Cancers (Basel). 13-17, pp.4379. https://doi.org/10.3390/cancers13174379
16 **Scientific paper**. 2021. Dynamic Intracellular Metabolic Cell Signaling Profiles During Ag-Dependent B-Cell Differentiation. Front Immunol. 12, pp.637832. https://doi.org/10.3389/fimmu.2021.637832
17 **Scientific paper**. 2021. Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Cancers (Basel). 13-6, pp.1454. https://doi.org/10.3390/cancers13061454
18 **Scientific paper**. 2020. Monocytes carrying GFAP detect glioma, brain metastasis and ischaemic stroke, and predict glioblastoma survival. Brain Commun. 3-1, pp.fcaa215. https://doi.org/10.1093/braincomms/fcaa215
19 **Scientific paper**. Botafogo V; Pérez-Andres M; Jara-Acevedo M; et al; (22/22) Almeida J*. 2020. Age distribution of multiple functionally relevant subsets of CD4+ T cells in human blood using a standardized and validated 14-color EuroFlow immune monitoring tube. Frontiers in Immunology. 27-11, pp.166. https://doi.org/10.3389/fimmu.2020.00166
20 **Scientific paper**. 2020. Authors reply to the Letter to Editor with regard to the article titled “Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping. Cytometry B Clin Cytom. https://doi.org/10.1002/cyto.b.21967
21 **Scientific paper**. P HORNA; SA WANG; KL WOLNIAK; et al; R TORRES; (5/9) J ALMEIDA. 2020. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics. Cytometry: Part B - Clinical Cytometry. Wiler. [published online ah. https://doi.org/10.1002/cyto.b.21878
22 **Scientific paper**. 2020. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: assay development/optimization, validation and ongoing quality monitors. Cytometry B Clin Cytom. https://doi.org/10.1002/cyto.b.21888
23 **Scientific paper**. 2020. Pericarditis and myocarditis long after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers. Preprints from medRxiv and bioRxiv.
24 **Scientific paper**. Muñoz-García N; Jara-Acevedo M; Caldas C; et al; * LAST AUTHORS; (18/19) Almeida J* (AC). 2020. STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features. Cancers. 12-12, pp.3508. https://doi.org/10.3390/cancers12123508
25 **Scientific paper**. M Pulitzer; P Horna; (3/3) J Almeida (AC) (AC). 2020. Sézary syndrome and mycosis fungoides: an overview, including the role of immunophenotyping.Cytometry: Part B - Clinical Cytometry. Wiley. Epub ahead of print. https://doi.org/10.1002/cyto.b.21888
26 **Scientific paper**. 2019. Complete multilineage CD4 expression defect associated with warts due to an inherited homozygous CD4 gene mutation. Frontiers in Immunology. 10-2502, pp.1-13. https://doi.org/10.3389/fimmu.2010.02502

27 **Scientific paper**. 2019. EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. Journal of Immunological Methods. 475, pp.112662. https://doi.org/10.1016/j.jim.2019.112662

28 **Scientific paper**. de Faria-Moss M; Yamamoto M; Arrais-Rodrigues C; et al; *Last authors; (14/15) Orfao A*. 2019. High frequency of chronic lymphocytic leukemia-like low-count monoclonal B-cell lymphocytosis in Japanese descendants leaving in Brazil. HAEMATOLOGICA. 105-6, pp.e298-e301. https://doi.org/10.3324/haematol.2019.230813

C.3. Research projects and contracts

1 **Project**. ECRIN-M3, Early Cancer Research Initiative Network on MBL (ECRIN-M3). Asociación Española Contra el Cáncer. J. Alberto Orfao de Matos. (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 01/07/2020-31/12/2025. 1.804.217 €. Principal investigator.

2 **Project**. COV20-00386, Impacto de la linfocitosis B monoclonal y del estado del sistema inmune en el desarrollo y evolución de la infección COVID-19 en adultos. Instituto de Salud Carlos III. Alberto Orfao. (IBSAL). 30/04/2020-30/06/2022. 106.017 €. Team member.

3 **Project**. Ref. PI20/01346, Next generation flow cytometry to approach knowledge of mature T/NK-cell malignancies: impact on diagnostic classification (Ref. PI20/01346). Instituto de Salud Carlos III. Julia Almeida Parra. (IBSAL). 01/01/2021-31/12/2021. 105.270 €. Principal investigator. IP

4 **Project**. POPTEC 0639 IDIAL-NET 3-E, Red Transfronteriza de Innovación en Diagnóstico Precoz de Leucemia para un envejecimiento saludable" (IDIAL-NET) - "Trans-border Network on Innovation in Early Diagnosis of Leukemia for healthy aging (IDIAL-NET)" (POPTEC 0639 IDIAL-NET 3-E). EU HORIZON H2020 (EP Interreg V A Spain-Portugal - POCTEP) (Y FONDOS FEDER). A. Orfao. (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 01/07/2019-31/12/2021. 419.658,75 €. Team member.

5 **Project**. GRS COVID 33/A/20, Estudio de la respuesta inmune y factores pronósticos asociados a la infección por SARS-Cov-2. GERENCIA REGIONAL DE SALUD DE CASTILLA Y LEON. Cristina Carbonell Muñoz. (HOSPITAL UNIVERSITARIO DE SALAMANCA). 01/06/2020-31/12/2020. 8.161 €. Team member.

6 **Project**. PI17/00399, "Identificación de factores involucrados en la ontopatogenia de la leucemia linfática crónica y de parámetros asociados a riesgo de transformación maligna en fases preleucémicas". Instituto de Salud Carlos III. Julia Almeida. (IBSAL). 01/01/2018-31/12/2020. 112.530 €. Principal investigator.

C.4. Activities of technology / knowledge transfer and results exploitation

1 **Patent of invention**. JJM van Dongen; A Orfao; C GONÇALVES GRUNHO TEODÓSIO; M Perez Andrés; J Almeida; W VAN DEN BOSSCHE; V BOTAFOGO GONCALVES; M BERKOWSKA; K VAN DER PAN; E Blanco Álvarez; AM DIKS; D PINTO DAMASCENO; A HERNÁNDEZ DELGADO. P119646NL00. Means and methods for multiparameter cytometry-based leukocyte subsetting Holland. 15/09/2019. University of Leiden, Paises Bajos.

2 **Patent of invention**. JJM Van Dongen; JA Orfao de Matos; J Flores Montero; JM Almeida Parra; VHJ Van Der Velden; S Böttcher; AC Rawstron; RM De Tute; LBS Lhermitte; V Asnafi; E Mejstrinova; T Szczepanski; PJ Monteiro de Silva Lucio; M Martín Ayuso; CE Pedreira. PCT/NL/2013/050420. "Methods, reagents and kits for flow cytometric immunophenotyping" Holland. 30/01/2018. Erasmus University Medical Center Rotterdam.

3 **Patent of invention**. VAN DONGEN JJM; ORFAO A; MONTERO-FLORES J; ALMEIDA J; VANDER VELDEN VHJ; BOTTCHER S; LANGERAK AK; MEJSTROKOVA E; SZCZEPANSKI T; RITGEN M; LUCIO. US 62/072,498. "Methods, reagents and kits for detecting minimal residual disease" Holland. 20/12/2017. Erasmus University Medical Center Rotterdam. CYTOGNOS, S.L.